Loading
A phase 2 trial of Datopotamab deruxtecan, Capecitabine, Fluorouracil in endometrial cancer and prostate cancer, run by AstraZeneca, now recruiting.
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) is a phase 2 interventional study registered as NCT05489211 by AstraZeneca, with 454 participants planned, started 2022-09-06 and due to reach its primary completion in 2027-10-01. Interventions recorded: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin. Conditions listed: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Rilvegostomig, Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer, AstraZeneca.
Shares Datopotamab deruxtecan, AstraZeneca, Carboplatin, Ovarian cancer.
Shares Rilvegostomig, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine, AstraZeneca.
Shares Rilvegostomig, Endometrial cancer, AstraZeneca, Antibody-drug conjugate (ADC).
Shares Fluorouracil (5-FU), Bevacizumab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Carboplatin.